Role of F-18-FDG-PET/CT in restaging of patients affected by gastrointestinal stromal tumours (GIST)

Nuclear Medicine Review

Volumn 13, Issue 2, 2010, Pages 76-80

  Bertagna, Francesco ^a   Bosio, Giovanni ^a   Orlando, Emanuela ^a   Biasiotto, Giorgio ^b   Giubbini, Raffaele ^b  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Gastrointestinal stromal tumours; GIST; Imatinib mesylate; PET; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; MALE; RETROSPECTIVE STUDY;

FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79958775179     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stamatakos M, Douzinas E, Stefanaki C, Safioleas R Polyzou E, Levidou G, Safioleas M. Gastrointestinal stromal tumor. World J Surg Oncol. 2009; 1: 7-61.
2. Agaram NP, Besmer P, Wong CC et al. Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clin Cancer Res 2007; 13: 170-181. (Pubitemid 46121866)
3. Joensuu H. Gastrointestinal stromal tumor (GIST). Annals of Oncology 2006; 17: 280-286.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001; 438: 1-12. (Pubitemid 32128184)
5. Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL: Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol 2008; 16: 241-250. (Pubitemid 351873723)
6. Jamali F, Darwiche S, El-Kinge N, Tawil A, Sowed A: Disease progression following Imatinib failure in gastrointestinal stromal tumors: Role of surgical therapy. The Oncologist 2007; 12: 438-442. (Pubitemid 46698721)
7. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231: 51-58. (Pubitemid 30043939)
8. Parfitt J, Streutker C, Riddell R, Driman D. Gastrointestinal stromal tumors: A contemporary review. Pathology - Research and Practice 2006; 202: 837-847. (Pubitemid 44743077)
9. Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-963. (Pubitemid 44615593)
10. Barnes G, Bulusu VR, Hardwick RH et al. A review of the surgical management of metastatic gastrointestinal stromal tumours (GISTs) on imatinib mesylate (Glivec). Int J Surg 2005; 3: 206-212. (Pubitemid 41550416)
11. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134. (Pubitemid 39296599)
12. Ponsaing L, Hansen MB: Therapeutic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol 2007; 13: 3316-3322. (Pubitemid 47062241)
13. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480. (Pubitemid 34879334)
14. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38 (Suppl 5): S60-S65.
15. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45: 17-21. (Pubitemid 47611603)
16. Reddy MP, Reddy P, Lilien DL. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med 2003; 28: 677-679. (Pubitemid 38281903)
17. Wilkinson MD, Fulham MJ. FDG PET imaging of metastatic gastrointestinal stromal tumor. Clin Nucl Med 2003; 28: 780-781. (Pubitemid 38295212)
18. Goerres GW, Stupp R, Barghouth G et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32: 153-162. (Pubitemid 40248485)
19. Kamiyama Y, Aihara R, Nakabayashi T et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29: 1429-1435. (Pubitemid 41712677)
20. Yamada M, Niwa Y, Matsuura T et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007; 42: 633-641. (Pubitemid 46633822)
21. Trent JC, Ramdas L, Dupart J et al. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor. Cancer 2006; 107: 1898-1908. (Pubitemid 44582961)
22. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759. (Pubitemid 46797957)
23. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004; 25: 433-438. (Pubitemid 38591102)
24. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005; 25: 4591-4594. (Pubitemid 41729517)
25. Basu S, Mohandas KM, Peshwe H, Asopa R, Vyawahare M. FDG-PET and PET/CT in the clinical management of gastrointestinal stromal tumor. Nucl Med Commun 2008; 29: 1026-1039.
26. Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-365. (Pubitemid 47618607)
27. Van den Abbeele AD. The lessons of GIST - PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 (Suppl 2): 8-13.